Moderna (MRNA) option implied volatility amid price movement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Brookline Capital Markets Reiterates Buy Rating on Moderna (MRNA)
June 10, 2024 8:58 AM EDTBrookline Capital Markets analyst Leah Rush Cann reiterated a Buy rating and $310.00 price target on Moderna (NASDAQ: MRNA).
The analyst comments "Todays announcement for positive phase III data for mRNA-1083, its combination flu + COVID-19 vaccine candidate, supports our outlook. Combination vaccines have the... More
Morgan Stanley Reiterates Equalweight Rating on Moderna (MRNA)
June 10, 2024 6:52 AM EDTMorgan Stanley analyst Matthew Harrison reiterated an Equalweight rating and $95.00 price target on Moderna (NASDAQ: MRNA).
The analyst comments "This morning MRNA announced that its Ph3 trial of mRNA-1083 (combo vaccine against influenza and COVID-19) has met its primary endpoints (LINK). We view this as an incremental positive for the stock as it could help bolster the tail of the COVID franchise, but we await further insight on the regulatory path. The ongoing Ph3 trial evaluated mRNA-1083 in two separate age groups of ~4,000 adults each. One consisted of adults 65 years and older,... More
Jefferies on Moderna (MRNA): 'Phase III Flu/Covid Combo looks good - could be on market in 2025'
June 10, 2024 6:52 AM EDTJefferies analyst Michael Yee reiterated a Buy rating and $180.00 price target on Moderna (NASDAQ: MRNA).
The analyst comments "Phase III data from MRNA's Covid+Flu combo vaccine today generally looks in-line with expectations and shows superior level of antibody titers in... More
